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Purpose: To evaluate the effect of systemic factors on best-corrected visual acuity (BCVA) achieved with
ranibizumab (Lucentis; Genentech, Inc, South San Francisco, CA) for treatment of diabetic macular edema (DME)
in the RIDE and RISE phase 3 studies.
Design: Exploratory, post hoc analysis of 2 randomized, double-masked, sham-injection controlled studies.
Participants: Adults with DME, BCVA of 20/40 to 20/320 Snellen equivalent, and central foveal thickness of
275 mm or more.
Methods: Analysis of RIDE (clinicaltrials.gov identiﬁer, NCT00473382) and RISE (clinicaltrials.gov identiﬁer,
NCT00473330) pooled ranibizumab data through month 24. Change in BCVA was assessed for association with
the following covariates: age, body mass index (BMI), blood pressure, serum glucose, glycosylated hemoglobin
(HbA1c), blood urea nitrogen, serum creatinine, estimated glomerular ﬁltration rate, and blood chemistry
variables. Change in BCVA at month 24 was assessed according to the following categories of diabetes medi-
cation use history: insulin only (n ¼ 193), insulin plus other medications (n ¼ 221), or other noninsulin medications
(n ¼ 331).
Main Outcome Measures: Change in BCVA from baseline assessed by randomized treatment group in
pooled 0.3- and 0.5-mg monthly ranibizumab groups.
Results: In patients with DME, vision improvement with ranibizumab was not inﬂuenced by systemic factors
such as diabetes medication history, serum glucose, HbA1c, renal function, BMI, and blood pressure. Patients
taking insulin with or without other medications at baseline had longer diabetes disease duration (mean, 17.4 and
20.9 years, respectively) compared with those taking other noninsulin medications (mean, 11.9 years). At month
24, among ranibizumab-treated patients, the mean BCVA change from baseline (Early Treatment Diabetic
Retinopathy Study letters  standard deviation) was not different between patients taking only insulin (12.611.2
letters), insulin plus other medications (12.212.4 letters), or other noninsulin medications (14.013.7 letters).
Mean BCVA change also was comparable among patients taking thiazolidinediones (12.99.7 letters) and those
not taking thiazolidinediones (13.213.3 letters).
Conclusions: There were no associations between systemic factors (baseline values or change from
baseline) and mean change of BCVA at month 24. These results suggest that visual response to ranibizumab
therapy in DME was not inﬂuenced by nonocular factors related to systemic management of diabetes in the RIDE
and RISE studies. Ophthalmology 2016;123:1581-1587 ª 2016 by the American Academy of Ophthalmology. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Intravitreal inhibitors of vascular endothelial growth factor
(VEGF) A have become ﬁrst-line treatment for patients with
diabetic macular edema (DME), based on data from several
large, prospective, randomized phase 3 clinical trials,
including Diabetic Retinopathy Clinical Research Network
protocol I,1 RIDE/RISE,2,3 RESOLVE,4 RESTORE,5
VIVID, and VISTA.6 Given that DME and diabetic
retinopathy are microvascular complications of diabetes, it
is important to investigate whether control of the
underlying disease has an impact on the outcomes with
intravitreal VEGF inhibition. Several studies have
demonstrated an association between the incidence or
progression of DME, or both, with metabolic factors such
as poor glycemic control7e9 and hypertension.8 The 2016 by the American Academy of Ophthalmology
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). Published by Elsevier Inc.relationship between glycosylated hemoglobin (HbA1c)
level and risk of microvascular complications is well
established,9 and HbA1c levels of 8% or more are
associated with a greater risk of DME (e.g., central foveal
thickness, 325 mm).7 Several reports also suggest that
abnormal values for metabolic factors related to the
severity of systemic diabetes disease severity (e.g., serum
creatinine, HbA1c, etc.) potentially may forecast visual or
anatomic response, or both, to anti-VEGF therapies.10e13
In a prospective study of 38 patients, inadequate control
of serum creatinine and cholesterol levels was shown to
correlate with poorer visual and anatomic outcomes with
anti-VEGF therapy.10 In a retrospective study of 124
patients, Matsuda et al12 recently showed that, in patients1581http://dx.doi.org/10.1016/j.ophtha.2016.03.038
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VEGFemediated improvements in BCVA and central
subﬁeld macular thickness were achieved than in patients
with HbA1c levels of 7% or less. Similar ﬁndings from 65
patients were reported by Ozturk et al,13 wherein
reduction in DME with anti-VEGF therapy was correlated
negatively with HbA1c level. However, these studies were
retrospective analyses, with variable follow-up and
nonstandardized treatment regimens. In contrast, in the
prospective, randomized, phase 3 RIDE and RISE studies,
which enrolled 759 patients, there was no signiﬁcant
difference in best-corrected visual acuity (BCVA) gains or
central foveal thickness (CFT) reduction in patients with
HbA1c levels of more than 7% compared with those with
HbA1c levels of 7% or less.14
Given the importance of understanding the relationship
between overall course of the underlying disease and treat-
ment outcomes in the eye and the conﬂicting ﬁndings re-
ported in the literature, it is important to continue exploring
the existing high-quality data from large phase 3 trials. In
the present study, we analyzed data from the RISE and
RIDE studies to determine whether any baseline systemic or
metabolic factors inﬂuenced BCVA improvement with
ranibizumab (Lucentis; Genentech, Inc, South San Fran-
cisco, CA).
Methods
Study Design and Participants
Details of methods and key ﬁndings from the RISE and RIDE trials
(ClinicalTrials.gov identiﬁers NCT00473330 and NCT00473382,
respectively) have been described in detail elsewhere.2 Brieﬂy,
RISE and RIDE were methodologically identical phase 3,
multicenter, double-masked, sham-injectionecontrolled, random-
ized studies of intravitreal ranibizumab (0.3 or 0.5 mg monthly) for
the treatment of DME. Studies were conducted in accordance with
the tenets of the Declaration of Helsinki and its amendments. Both
studies received approval from the relevant institutional review
boards and ethics committees, and all participants provided
informed consent. Enrolled participants were 18 years of age or
older, had decreased vision resulting from DME (study eye BCVA,
20/40e20/320 Snellen equivalent), and central subﬁeld thickness
of at least 275 mm (measured with time-domain optical coherence
tomography). Patients were randomized to monthly sham in-
jections or intravitreal ranibizumab 0.3 mg or 0.5 mg through
month 24. Macular laser was permitted beginning at month 3 as per
protocol-speciﬁed criteria and an assessment by the evaluating
physician that macular laser will be beneﬁcial. In the third year,
sham patients, while still masked, were eligible to cross over to
monthly 0.5-mg ranibizumab treatment.
Assessments
The current analysis considered only double-masked, sham-
injectionecontrolled data from the 2 ranibizumab arms up to the
primary end point at month 24. Because efﬁcacy outcomes in the
RISE and RIDE trials were similar for the 0.3-mg and 0.5-mg
ranibizumab treatment groups,2 data for these groups were
pooled for this analysis. The relationship between change in
BCVA with ranibizumab treatment from baseline through
month 24 and the following covariates related to systemic or
metabolic function, or both, were assessed: age; body mass1582index (BMI); blood pressure (systolic and diastolic); markers of
glycemic control factors, including HbA1c and blood glucose
levels; blood chemistry, including albumin, hemoglobin,
hematocrit, and total protein; and markers of renal function,
including baseline serum creatinine, estimated glomerular
ﬁltration rate, and blood urea nitrogen.
In a separate analysis of data from the RIDE and RISE
studies, the effect of HbA1c on BCVA and central foveal
thickness was analyzed according to better or worse glycemic
control, using a cutoff threshold of 7.0%.14 Herein, we conducted
a more detailed assessment of the potential effects of systemic
covariates and change in BCVA over time using ordinary least-
squares regression and locally weighted linear regression
smoothing curves. The association between systemic factors and
BCVA was assessed according to baseline covariate values
versus change in BCVA over time and according to change in
systemic covariates from baseline versus change in BCVA over
time. Systemic characteristics of patients at baseline were eval-
uated using Student’s t test. A multivariate analysis was planned
for any variables found to be signiﬁcant at the 0.2 signiﬁcance
level in univariate analysis. Diabetes medication status at base-
line and change in BCVA at month 24 also were assessed.
Medication categories were deﬁned as insulin alone, insulin in
combination with other antidiabetic drugs, only noninsulin anti-
hyperglycemic medications, and no antidiabetic drugs. Addi-
tionally, we looked at use of thiazolidinediones at baseline and
change in BCVA at month 24. These analyses were exploratory
and were not based on statistical hypotheses. All analyses were
performed using SAS software version 9.4 (SAS Institute, Cary,
NC).Results
Laboratory parameters and blood pressure values at baseline and
at month 24 (Table 1) were similar for the patients randomized
to sham injection or ranibizumab (pooled 0.3-mg and 0.5-mg
groups). In patients receiving ranibizumab, mean HbA1c level
was 7.7% (standard deviation [SD], 1.4%) at baseline and 7.8%
(SD, 1.6%) at month 24 (P ¼ 0.08). The directionality of the
changes from baseline to month 24 was similar between the
sham and ranibizumab patients. Systolic and diastolic blood
pressure, total protein, and estimated glomerular ﬁltration rate all
decreased at month 24 with respect to baseline. Blood glucose,
blood urea nitrogen, and serum creatinine increased at month 24
compared with baseline. However, in both univariate and
multivariate analyses, the only characteristic that was associated
signiﬁcantly with BCVA change at month 24 was patient age
(P ¼ 0.03; Fig 1A).
Change in BCVA at month 24 was not associated with
baseline BMI (P ¼ 0.49; Fig 1), baseline systolic blood pressure
(P ¼ 0.38), baseline diastolic blood pressure (P ¼ 0.36), change
in systolic blood pressure (P ¼ 0.82), or change in diastolic
blood pressure (P ¼ 0.83). In addition, there was no
relationship between month 24 BCVA change and baseline
HbA1c level (P ¼ 0.83; Fig 2), baseline blood glucose level
(P ¼ 0.23), or change in either of these parameters at
month 24 (P ¼ 0.23 and P ¼ 0.26, respectively). Measures of
blood chemistry and renal factors yielded similar results, with
baseline and month 24 change in serum creatinine (P ¼ 0.97
and P ¼ 0.76, respectively) and baseline and month 24 change
in estimated glomerular ﬁltration rate (P ¼ 0.78 and P ¼ 0.88,
respectively) all showing no association with change in BCVA
at month 24 (Fig 3).
Month 24 change in BCVA was analyzed as a function of
antihyperglycemic medication use. Mean  SD duration of
Table 1. Systemic Patient Characteristics at Baseline and Month 24
Systemic Characteristics, Mean (Standard Deviation)
Sham Injection Ranibizumab (0.3-mg and 0.5-mg Groups Pooled)
Baseline (n ¼ 257) Month 24 (n ¼ 204) Baseline (n ¼ 502) Month 24 (n ¼ 415)
Age (yrs) 62.7 (10.3) d 62.2 (10.1) d
Body mass index (kg/m2) 31.6 (7.0) d 31.7 (6.5) d
Diastolic blood pressure (mmHg) 76.5 (10.7) 73.4 (10.5) 77.5 (10.2) 75.2 (10.4)
Systolic blood pressure (mmHg) 135.9 (19.4) 132.6 (17.6) 138.1 (18.1) 134.4 (18.5)
Blood chemistry proﬁle (g/dl)
Albumin 3.9 (0.4) 3.9 (0.4) 3.9 (0.4) 3.8 (0.4)
Total protein 7.2 (0.5) 7.1 (0.5) 7.2 (0.5) 7.0 (0.5)
Hematology
Hemoglobin (g/dl) 12.8 (1.5) 12.6 (1.6) 12.9 (1.6) 12.7 (1.6)
Hematocrit (%) 38.8 (4.5) 38.4 (4.6) 39.1 (4.8) 38.9 (4.6)
Glycemic control
Blood glucose (mg/dl) 150.0 (64.7) 168.4 (84.6) 148.7 (66.1) 179.0 (84.9)
Hemoglobin A1c (%) 7.7 (1.4) 7.7 (1.7) 7.7 (1.4) 7.8 (1.6)
Renal function
Blood urea nitrogen (mg/dl) 24.4 (11.6) 26.5 (14.3) 25.0 (11.5) 27.7 (13.6)
Creatinine (mg/dl) 1.1 (0.5) 1.4 (0.9) 1.2 (0.6) 1.5 (1.2)
Estimated GFR (ml/minute/1.73 m2) 74.1 (26.5) 64.1 (25.5) 72.9 (28.2) 61.1 (26.2)
d ¼ age and body mass index not determined at month 24; GFR ¼ glomerular ﬁltration rate.
Data are mean  standard deviation.
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years) or taking insulin with other agents (17.48.4 years) versus
those taking other antidiabetic agents (11.98.5 years) or taking no
diabetes medications (11.08.5 years). Mean  SD duration of
DME was comparable across medication use categories: 2.32.7
years in those taking insulin only, 2.22.7 years in those taking
insulin with other agents, 1.92.3 years in patients taking non-
insulin agents, and 1.41.7 years in patients not taking diabetes
medications. There were no apparent differences among visual
outcomes in patients taking insulin alone, patients taking insulin
with other antihyperglycemic medications, patients taking only
noninsulin antihyperglycemic medications, or those taking or not
taking thiazolidinediones (Fig 4).Discussion
Previous assessment of data from RIDE and RISE using a
categorical distribution showed that patients with an HbA1c
level of more than 7% had visual outcomes that were
comparable with those in patients with an HbA1c level of
less than 7%.14 We conducted a more detailed assessment of
the relationship between changes in BCVA in patients
randomized to 24 months of ranibizumab treatment in the
RISE and RIDE trials with a range of systemic and
metabolic characteristics, both at baseline and as they may
have changed during treatment. With the exception of age,
we found no compelling evidence that systemic factors
such as glycemic control, blood chemistry, or renal
function were associated with BCVA outcomes in
response to ranibizumab treatment. Similarly, we found no
evidence that BCVA outcomes differed according to the
class of antihyperglycemic medications being used for
treatment of diabetes. Although thiazolidinediones are
associated with macular edema, the lack of difference in
visual outcomes between patients taking or not takingthiazolidinediones suggests equal efﬁcacy of ranibizumab
in these 2 groups.
It should be noted that patients with severely uncon-
trolled diabetes, as evidenced by an HbA1c level of more
than 12%, were excluded from the RIDE and RISE trials. As
expected for patients living with diabetes on average for
15 years (mean, 14.5e16.6 years at baseline), laboratory
values at baseline reﬂected chronically abnormal glucose
metabolism and microvascular disease (Table 1). The
RIDE and RISE trial participants seemed to be reasonably
well controlled during the 24-month period, with a mean
HbA1c level of approximately 7.7% and changes in labo-
ratory values not indicating meaningful change in clinical
severity in the sham or ranibizumab arms. The lack of
patients with severely uncontrolled diabetes represents a
potential limitation of our analysis. However, these patients
constitute a minority of those seen in clinical practice. For
example, the Centers for Disease Control and Prevention
reported that, among patients with diabetes between 2003
and 2006, most (87%) had HbA1c levels between 6% and
9%, whereas only 13% had HbA1c levels of more than
9%.15
Consistent with our ﬁndings, a Diabetic Retinopathy
Clinical Research Network analysis of 361 eyes of patients
with DME treated using ranibizumab with prompt or
deferred laser photocoagulation found no association of
changes in BCVA or central subﬁeld thickness for HbA1c,
hypertension, or renal disease, whereas younger age
(<60 years vs. 60 years) was found to be associated with
greater improvements in BCVA.11
Findings from smaller studies are less consistent. For
example, a case-series study of the anti-VEGF treatment
bevacizumab in 38 patients (45 eyes) with DME found, as
in the present study, that there was no association of
treatment beneﬁts with hypertension.10 However, that1583
Figure 1. Scatterplots showing change in best-corrected visual acuity (BCVA) at month 24 versus (A) baseline age, (B) baseline body mass index, (C)
systolic and (D) diastolic blood pressure at baseline, and 24-month change in (E) systolic and (F) diastolic blood pressure. Lines represent local regression
smoothing, and shaded areas represent 95% conﬁdence intervals. P values are from linear regression models. ETDRS ¼ Early Treatment Diabetic Reti-
nopathy Study.
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Figure 2. Scatterplots showing change in best-corrected visual acuity (BCVA) at month 24 versus (A) glycosylated hemoglobin (HbA1c) at baseline, (B)
blood glucose at baseline, and 24-month change in (C) HbA1c and (D) blood glucose. Lines represent local regression smoothing, and shaded areas
represent 95% conﬁdence intervals. P values are from linear regression models. ETDRS ¼ Early Treatment Diabetic Retinopathy Study.
Singh et al  Systemic Factors and Ranibizumab for DMEstudy suggested that factors including poor glycemic
control, longer duration of diabetes, serum creatinine
levels, and nephropathy may predict a poor response to
treatment. An additional retrospective case series of 124
patients with DME identiﬁed that glycemic control
lasting for more than 1 year was associated with an
improved response to bevacizumab, but no association of
treatment outcomes was found for patient age, duration
of diabetes, serum creatinine, BMI, or blood pressure.12
Finally, a retrospective case-series study of 65 patients
(65 eyes) found that short-term changes in central subﬁeld
thickness were correlated negatively with HbA1c levels
after a single injection of ranibizumab.13 There is no clear
explanation for the differences between our ﬁndings and
those of earlier studies. However, comparisons made
across different studies may be affected by differences in
study design and patient populations. For example,
patients in the clinical trial setting typically are monitored
more closely than in real-word circumstances, and studies
differ in sample size (i.e., earlier studies had smaller
sample sizes), inclusion criteria, study duration, study
medications, or a combination thereof. These may becontributing factors to the differences observed across
published analyses of HbA1c levels in patients receiving
anti-VEGF for DME.
The size and prospective nature of the RIDE and RISE
clinical trials, on which the present ad hoc analysis is
based, are relative strengths compared with the retro-
spective design of other earlier studies.7 The lack of
consistency among previous studies and in consideration
of the present data illustrate the challenges inherent in
the use of post hoc analyses, which are not powered to
provide deﬁnitive evidence for associations of treatment
beneﬁt. Nonetheless, it is important to consider that in
the large, well-selected patient population derived from
the RIDE and RISE studies, we did not observe any as-
sociation between metabolic factors and BCVA change in
response to ranibizumab treatment over the 24-month
study period, further conﬁrmed on multivariate analysis.
Based on these data from the RIDE and RISE studies,
improvement in vision with ranibizumab was independent
of patient characteristics such as glycemic control, dia-
betes medication history, blood pressure, BMI, or renal
function.1585
Figure 3. Scatterplots showing change in best-corrected visual acuity (BCVA) at month 24 versus (A) baseline serum creatinine, (B) baseline estimated
glomerular ﬁltration rate (eGFR), and 24-month change in (C) serum creatinine and (D) eGFR. Lines represent local regression smoothing, and shaded
areas represent 95% conﬁdence intervals. P values are from linear regression models. ETDRS ¼ Early Treatment Diabetic Retinopathy Study.
Figure 4. Bar chart showing change in best-corrected visual acuity (BCVA) in ranibizumab-treated patients as a function of antihyperglycemic medications
class. Bars indicate standard deviation. Not shown: 7 subjects were not taking medication at baseline. ETDRS ¼ Early Treatment Diabetic Retinopathy
Study; TZD ¼ thiazolidinedione.
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